Presence of kisspeptin-like immunoreactivity in human adrenal glands and adrenal tumors.
Takahashi. Kazuhiro K; Shoji. Itaru I; Shibasaki. Akiko A; Kato. Ichiro I; Hiraishi. Keisuke K; Yamamoto. Hajime H; Kaneko. Kiriko K; Murakami. Osamu O; Morimoto. Ryo R; Satoh. Fumitoshi F; Ito. Sadayoshi S; Totsune. Kazuhito K
Key Findings
- Kisspeptin-like immunoreactivity was found in all normal adrenal glands and adrenal tumor samples studied.
- There were no significant differences in kisspeptin levels between normal adrenal tissue and aldosterone‑producing adenomas, cortisol‑producing adenomas, adrenocortical carcinomas, or pheochromocytomas.
- Immunostaining showed the strongest kisspeptin signal in the adrenal medulla compared to the cortex and tumor tissues.
Practical Outcomes
- This finding confirms that kisspeptin is a native component of adrenal tissue, but the study does not provide actionable guidance on dosing, supplementation, or performance‑enhancing protocols for biohackers.
Summary
Scientists discovered that the hormone‑like peptide kisspeptin is naturally present in human adrenal glands and in various adrenal tumors, with similar amounts across normal tissue and different tumor types, and it’s especially strong in the adrenal medulla.
Abstract
Kisspeptins are neuropeptides which activate the hypothalamo-pituitary gonadal axis and are considered to play important physiological roles in the reproduction. Kisspeptins have also been reported to stimulate the aldosterone secretion from the adrenal cortex. However, the expression of kisspeptins in human adrenal glands and adrenal tumors has not been clarified yet. We, therefore, studied the presence of kisspeptin-like immunoreactivity (LI) in human adrenal glands and adrenal tumors (adrenocortical adenomas, adrenocortical carcinomas, and pheochromocytomas) by radioimmunoassay and immunocytochemistry. Kisspeptin-LI was detected in all the tissues examined; normal portions of adrenal glands (3.0 +/- 2.3 pmol/g wet weight, n = 21, mean +/- SD), aldosterone-producing adenomas (4.6 +/- 3.3 pmol/g wet weight, n = 10), cortisol-producing adenomas (2.7 +/- 1.4 pmol/g wet weight, n = 14), adrenocortical carcinomas (1.7 +/- 0.2 pmol/g wet weight, n = 4), and pheochromocytomas (1.8 +/- 0.8 pmol/g wet weight, n = 6). There was no significant difference in kisspeptin-LI levels among them. Immunocytochemistry showed positive kisspeptin-immunostaining in normal adrenal glands, with stronger immunostaining found in the medulla. Furthermore, positive kisspeptin-immunostaining was found in all types of adrenal tumors examined; adrenocortical adenomas, adrenocortical carcinomas, and pheochromocytomas. The intensity of kisspeptin-immunostaining in these adrenal tumors was, however, not so strong as that in normal adrenal medulla. The present study has shown for the first time the presence of kisspeptin-LI in adrenal glands and adrenal tumors.
Study Information
pubmed
2009
2009-11-07T00:00:00.000Z
10.1007/s12031-009-9306-4
11
28